Ex-Dyne team members reconvene at Crescent

As Crescent Biopharma Inc. prepares to close its reverse merger with GlycoMimetics Inc. (NASDAQ:GLYC), the bispecific and antibody-drug conjugates developer has introduced Joshua Brumm as its new CEO, among other C-suite appointments. A former CEO of Dyne Therapeutics Inc. (NASDAQ:DYN), Brumm became a general partner at Forbion last year with the goal of building its U.S. presence.

More former Dyne employees joined Crescent as well, with Jonathan McNeill becoming president and COO and Rick Scalzo taking the CFO role. Crescent also named Ellie Im CMO; she had been SVP of clinical development at Centessa Pharmaceuticals plc (NASDAQ:CNTA). Crescent is preparing to start clinical testing of its bispecific targeting PD-1 and VEGF...